Off-the-Shelf CAR t cells take on tough lymphomas

NCT ID NCT03939026

Completed Disease control Sponsor: Allogene Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new type of cell therapy called ALLO-501, made from donor cells rather than the patient's own cells, in 50 adults with lymphoma that had come back or stopped responding to treatment. The therapy targets CD19, a protein on cancer cells, and was given after a short chemotherapy course to prepare the body. The main goals were to check safety and find the right dose, with early signs of effectiveness also being monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALLO-501 (a type of immune cell therapy made from donor cells, called allogeneic CAR T cells) and ALLO-647 (an antibody that helps prepare the body for the cell therapy)
What this could lead to: If this works, it could offer a ready-made, off-the-shelf cell therapy for people with hard-to-treat lymphomas, potentially avoiding the long wait and high cost of personalized CAR T treatments.
What could go wrong: This is an early, small Phase 1 trial focused on safety, so it is not yet proven to work. There are risks of serious side effects like cytokine release syndrome or nervous system problems, and the therapy may not control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
MD Anderson

Houston, Texas, 77030, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
St. Davids South Austin Medical Center

Austin, Texas, 78704, United States
Stanford University

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.